Alten: H1 13 analysts' meeting feedback: market recovery confirmed

NEUTRAL, Fair Value EUR32 vs. EUR28 (+5%)

News published on September Wednesday 25, 2013
Share on

We reiterate our Neutral rating but raise our DCF-derived fair value to EUR32 from EUR28 following yesterday’s analysts’ meeting, as: 1). We increase our adj. EPS forecasts by 6% for 2013 and 4% for 2014-15 (+EUR1); 2). We now consider that with a market cap of EUR1bn, Alten’s beta should be lower than that previously (1.6 vs. 1.8) in our model (+EUR3). Market recovery on High-tech Consulting is confirmed, and Alten is poised to benefit from it from Q4 13 with better growth and higher margins. That said, following an 18% share price rebound over the last three months, we keep our Neutral rating as the company has limited leverage on its operating margin in our view. 

Full report available to subscribers
Please contact  

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities